A Celebration of Life

Total Page：16

File Type：pdf, Size：1020Kb

A Celebration of Life James Alexander Block March 29, 1937 - May 7, 2020 A Celebration of the Life of James Alexander Block Order of Service “Begin the Beguine”..............................................................Artie Shaw Welcome............................................................................Willis Turner Slide Show: “Cheek To Cheek”.......Ella Fitzgerald and Louis Armstrong Tributes and Remembrances...............................................Peter Block Alexis Romay Vanessa Block Milo Romay Jeremy Block Tom Block Peggy Block Danziger Emanuelle Block Dr. Phyllis August Robie and Susie Hermanos Morris Copeland Adrianne and Bill Silver Rosemerie Marion Sally Schwartz Barbara Block Concluding Remarks......................................................... Valerie Block “Love Is Here To Stay”....................Ella Fitzgerald and Louis Armstrong Jim was born to Melvin Block and Anita Wangrowe Block in 1937, and grew up in New York City. He graduated from Dartmouth College, Phi Beta Kappa, in 1959, and joined the family business, Block Drug Company, shortly thereafter. Jim’s grandfather, Alexander Block, a Lithuanian Jew who had immigrated to the United States alone at the age of 12, started a company in Brooklyn, NY, as a small wholesale business; it later became an international consumer dental and packaged goods company whose brands included Sensodyne, Polident and Nytol. Jim held various positions at Block Drug Company starting in 1959, including serving as Chairman of the Board from 1988 to 2001, when the company was purchased by GlaxoSmithKline. Jim spent much time and energy working to make the world a better place. He served on the board of The Associated Y’s of the Federation of Jewish Philanthropy. He also served on the board of Columbia University’s School of Social Work, the Hexter and Block Vacation Center for Senior Citizens, The Dalton School, and The US Fund for Unicef. He was an overseer at the Hood Museum of Art at Dartmouth College, and a member of the Board of the National Museum of the American Indian in Washington, DC and the Heye Center in New York City. Jim was honored by the Smithsonian Institution in appreciation for his service and dedication to the NMAI. He was named a Fellow of the American Academy of Arts and Sciences. Jim always lived in Manhattan, and was a true New Yorker, spending his free time in museums, concert halls and theaters. He married Barbara Heller in 1960; they would have celebrated their 60th wedding anniversary in June of 2020. His friends and family appreciated his keen intelligence, his delightful sense of humor and dry wit. His favorite pastimes included crosswords and reading; he had an encyclopedic knowledge of geography, art and history. He is survived by his wife, Barbara; his sister, Susan Stearns; his daughter, Valerie Block, and her husband Alexis Romay; his son, Peter Block, and his wife Judith Klugman; and three grandchildren, Vanessa Block, Jeremy Block and Milo Romay. He is sorely missed..

Copy Link

Recommended publications

In This Section
Strategic report In this section Chairman’s statement 2 CEO’s review 4 Business overview 6 The global context 8 Our business model 12 Our strategic priorities 14 How we performed 16 Risk management 18 Grow 20 Deliver 32 Simplify 44 Our financial architecture 48 Responsible business 50 Financial review 58 Strategic report Chairman’s statement Chairman’s statement To shareholders The value of the significant changes that have been made in recent years is evidenced in our performance this year “ Since Sir Andrew became It is clear from the following pages that Through the Audit & Risk Committee, we the Group made good progress against oversee the issues and challenges faced by CEO, the company has its strategy in 2013. management, and encourage the creation of an environment in which GSK can achieve The Board believes the business is seeing returned £30 billion its strategic ambitions in a responsible and the benefits of the significant changes the sustainable manner. to shareholders.” management team has driven over recent years to deliver sustainable growth, reduce risk and I have no doubt that commercial success is enhance returns to shareholders. directly linked to operating in a responsible way and which meets the changing expectations of The notably strong performance from the society. In this respect, the company continues R&D organisation in 2013 – with six major to adopt industry-leading positions on a range new product approvals in areas including of issues. respiratory disease, HIV and cancer – is critical to the longer-term prospects of the The announcement of plans during 2013 to Group.
[Show full text]
Glaxosmithkline Plc Annual Report for the Year Ended 31St December 2000
GlaxoSmithKline 01 GlaxoSmithKline plc Annual Report for the year ended 31st December 2000 Contents Report of the Directors 02 Financial summary 03 Joint statement by the Chairman and the Chief Executive Officer 05 Description of business 29 Corporate governance 37 Remuneration report 47 Operating and financial review and prospects 69 Financial statements 70 Directors’ statements of responsibility 71 Report by the auditors 72 Consolidated statement of profit and loss 72 Consolidated statement of total recognised gains and losses 74 Consolidated statement of cash flow 76 Consolidated balance sheet 76 Reconciliation of movements in equity shareholders’ funds 77 Company balance sheet 78 Notes to the financial statements 136 Group companies 142 Principal financial statements in US$ 144 Financial record 153 Investor information 154 Shareholder return 156 Taxation information for shareholders 157 Shareholder information 158 Share capital 160 Cross reference to Form 20-F 162 Glossary of terms The Annual Report was approved by the Board 163 Index of Directors on 22nd March 2001 and published on 12th April 2001. Contact details 02 GlaxoSmithKline Financial summary 2000 1999 Increase Business performance £m £m CER % £ % Sales 18,079 16,164 9 12 Trading profit 5,026 4,378 12 15 Profit before taxation 5,327 4,708 11 13 Earnings/Net income 3,697 3,222 13 15 Earnings per Ordinary Share 61.0p 52.7p 14 16 Total results Profit before taxation 6,029 4,236 Earnings/Net income 4,154 2,859 Earnings per Ordinary Share 68.5p 46.7p Business performance: results exclude merger items and restructuring costs; 1999 sales and trading profit exclude the Healthcare Services businesses which were disposed of in 1999.
[Show full text]
Today's Research Tomorrow's Cure
2018 Heart Research Institute Annual Review Accelerating Research Tomorrow’s cure Tomorrow’s Today’s research Today’s 2018 Heart Research Institute Annual Review Hello Future Accelerating 2018 Heart Research Institute Annual Review Research ACCELERATING Discoveries into therapies Knowledge into prevention Breakthroughs into cures Students into leaders Collaborations into partnerships 4 2018 Heart Research Institute Annual Review Inspiring Leaders 2018 Heart Research Institute Annual Review CONTENTS 06 HRI in 2018 08 Chairman’s Report 2018 10 Director of Cardiovascular Research Report 12 2018 Research and Media Highlights 16 Applied Materials Group 18 Atherosclerosis and Vascular Remodelling Group 20 Cardiac Imaging Group 22 Cardiometabolic Disease Group 24 Cardiovascular Medical Devices Group 26 Cell Therapeutics Group 28 Clinical Research Group 30 Haematology Research Group 32 Heart Rhythm and Stroke Prevention Group 34 High Blood Pressure Group 36 Thrombosis Group 38 Vascular Complications Group 40 Vascular Immunology Group 42 Inflammation and Fibrosis Research 44 PhD Students 45 Select Prizes and Awards 46 Select Conferences and Presentations 50 Select Publications 56 Board of Governors 59 International Board of Governors 60 Members of the Institute 62 Fundraising Report 66 Operations Report 6 2018 Heart Research Institute Annual Review The mission of the Heart Research Institute (HRI) is to prevent death and suffering from cardiovascular disease through an understanding of the biological processes that cause atherosclerosis and thrombosis, the major underlying causes of most heart attacks and strokes. 20 18 SHORT TERM LONG TERM The major short-term focus of our research There are four long-term objectives is to understand the development and for our research: progression of atherothrombotic conditions • To investigate mechanisms in which the arteries are narrowed and contributing to the pathogenesis restricted due to a build-up of fatty of cardiovascular disease.
[Show full text]
Building Innovation, Performance and Trust
Building Innovation, Performance and Trust Emma Walmsley, CEO Cautionary statement regarding forward-looking statements This presentation may contain forward-looking statements. Forward-looking statements give the Group’s current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as ‘anticipate’, ‘estimate’, ‘expect’, ‘intend’, ‘will’, ‘project’, ‘plan’, ‘believe’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulations, UK Listing Rules and the Disclosure and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Investors should, however, consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the US Securities and Exchange Commission (SEC). All investors, wherever located, should take note of these disclosures. Accordingly, no assurance can be given that any particular expectation will be met and investors are cautioned not to place undue reliance on the forward-looking statements. Forward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which relate to factors that are beyond the Group’s control or precise estimate.
[Show full text]
2009 Nhamcs Micro-Data File Documentation Page 1
2009 NHAMCS MICRO-DATA FILE DOCUMENTATION PAGE 1 ABSTRACT This material provides documentation for users of the public use micro-data files of the 2009 National Hospital Ambulatory Medical Care Survey (NHAMCS). NHAMCS is a national probability sample survey of visits to hospital outpatient and emergency departments, conducted by the National Center for Health Statistics, Centers for Disease Control and Prevention. The survey is a component of the National Health Care Surveys, which measure health care utilization across a variety of health care providers. There are two micro-data files produced from NHAMCS, one for outpatient department records and one for emergency department records. Section I of this documentation, “Description of the National Hospital Ambulatory Medical Care Survey,” includes information on the scope of the survey, the sample, field activities, data collection procedures, medical coding procedures, and population estimates. Section II provides detailed descriptions of the contents of each file’s data record by location. Section III contains marginal data for selected items on each file. The appendixes contain sampling errors, instructions and definitions for completing the Patient Record forms, and lists of codes used in the survey. PAGE 2 2009 NHAMCS MICRO-DATA FILE DOCUMENTATION SUMMARY OF CHANGES FOR 2009 The 2009 NHAMCS Emergency Department and Outpatient Department public use micro-data files are, for the most part, similar to the 2008 files, but there are some important changes. These are described in more detail below and reflect changes to the survey instrument, the Patient Record form. Emergency Departments 1. New or Modified Items a. In item 1, Patient Information, there is a new checkbox item “Arrival by Ambulance.” This replaces the 2008 item, “Mode of Arrival.” b.
[Show full text]
Glaxosmithkline Annual Report 2010
Do more, feel better, live longer GlaxoSmithKline Annual Report 2010 Contents Business review P08–P57 Business review 2010 Performance overview 08 Research and development 10 Pipeline summary 12 Products, competition and intellectual property 14 Regulation 18 Manufacturing and supply 19 Business review World market 20 This discusses our financial and non-financial activities, GSK sales performance 21 resources, development and performance during 2010 Segment reviews 22 and outlines the factors, including the trends and the Responsible business 29 principal risks and uncertainties, which are likely to Financial review 2010 34 affect future development. Financial position and resources 41 Financial review 2009 47 Governance and remuneration Risk factors 53 This discusses our management structures and governance procedures. It also sets out the Governance and remuneration P58–P101 Governance and remuneration Governance and remuneration remuneration policies operated for our Directors and Our Board 58 Corporate Executive Team members. Our Corporate Executive Team 60 Governance and policy 64 Financial statements Dialogue with shareholders 69 The financial statements provide a summary of the Internal control framework 71 Group’s financial performance throughout 2010 and its Committee reports 74 position as at 31st December 2010. The consolidated Remuneration policy 84 financial statements are prepared in accordance with Director terms and conditions 91 IFRS as adopted by the European Union and also IFRS as Director and Senior Management remuneration 94 issued by the International Accounting Standards Board. Directors’ interests 96 Directors’ interests in contracts 101 Shareholder information This includes the full product development pipeline and discusses shareholder return in the form of dividends and share price movements.
[Show full text]
Glaxosmithkline, Parent Company of Stiefel, a GSK Company
Dermatology on Wall Street GlaxoSmithKline, Parent Company of Stiefel, a GSK Company or more than 160 years, Stiefel, a GSK compa- ny, has been committed to dermatology. Following a series of acquisitions in the latter Fpart of the last decade (Connetics Corp. in 2006 and Barrier Therapeutics in 2008), Stiefel itself was acquired by GlaxoSmithKline (GSK) in July 2009. GSK, a global pharmaceutical company, GSK (NYSE: GSK) Founded: 2000 has the third highest revenues of any pharmaceuti- (Merger of Glaxo Wellcome and SmithKline Beecham) cal company globally. The company’s primary therapeutic areas include asthma, anti-virals, anti- Stiefel Founded: 1847, Acquired by GSK in 2009 infectives, cancer, diabetes, mental health, and now dermatology. Its large consumer division mar- Based: London, UK and Research Triangle Park, NC (Stiefel) kets several market-leading products, including the Number of Employees: 96,500+ world’s fastest growing toothpaste brand for the last five years (Sensodyne). On the Web: www.gsk.com Since the acquisition, Stiefel remains focused on www.stiefel.com dermatology, with a portfolio of OTC and prescrip- tions drugs for the treatment in a wide range of Officers: Andrew Witty, Chief Executive Office; Simon Bicknell, dermatologic therapeutic areas, including acne, Senior Vice President, Governance, Ethics and Assurance; John psoriasis, aesthetics, antifungal, anti-itch, and dry Clarke, President, Consumer Healthcare; Deirdre Connelly, skin. President, North American Pharmaceuticals; Simon Dingemans, Stiefel’s development in recent years has Chief Financial Officer; Marc Dunoyer, President, Asia focused on novel foam vehicle formulations, Pacific/Japan; Eddie Gray, President, Pharmaceuticals Europe; including recent additions Sorilux (calcipotriene) Abbas Hussain, President, Emerging Markets and Asia Pacific; and Extina (ketoconazole), and the antibacterial Altabax (retapamulin ointment).
[Show full text]
FAMIS Formulary (Current)
VIRGINIA PREMIER HEALTH PLAN FAMIS MEDICAID FORMULARY PLEASE NOTE: Check your benefit materials for the specific drugs covered and the copayments for your prescription drug program. For specific questions about your coverage, please call the phone number printed on your ID card. The list may not be all- inclusive. THIS LIST IS SUBJECT TO CHANGE. For the member: Generic medications contain the same active ingredients as their corresponding brand-name medications, although they may look different in color or shape. They have been FDA-approved under strict standards. For the physician: Please prescribe preferred products and allow generic substitutions when medically appropriate. Thank you. CURRENT AS OF 10/1/2021 Requirements/Limits AGE = Age limit requirement Custom = Drug has unique restrictions OTC = Over the Counter PA = Prior Authorization required QL = Quantity Level Limit lowercase italics = Generic Formulary SP = Specialty Drug. Preferred Specialty drugs Pharmacy will be listed if applicable UPPERCASE = Brand name Formulary Formulary Status ST = Step Therapy may apply to some or all drugs Formulary = Covered strengths of the drug Drug Name Formulary Status Requirements/Limits 1st relief spray external liquid 4-1 % Formulary OTC 1st tier unifine pentips 29g x 12mm , 31g x 5 mm , 31g x 6 Formulary OTC; QL (200 EA per 30 days) mm , 31g x 8 mm , 32g x 4 mm 1st tier unilet comfortouch Formulary OTC; QL (150 EA per 30 days) 4-N-1 EXTERNAL CREAM 1 % Formulary OTC 50+ adult eye health oral capsule Formulary OTC A & D ZINC OXIDE EXTERNAL
[Show full text]
Case No COMP/M.2192 - 3* SMITHKLINE BEECHAM / BLOCK DRUG
EN Case No COMP/M.2192 - 3* SMITHKLINE BEECHAM / BLOCK DRUG Only the English text is available and authentic. REGULATION (EEC) No 4064/89 MERGER PROCEDURE Article 6(1)(b) NON-OPPOSITION Date: 11/01/2001 Also available in the CELEX database Document No 301M2192 Office for Official Publications of the European Communities L-2985 Luxembourg COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 11.01.2001 SG(2000)D/285020 In the published version of this decision, some PUBLIC VERSION information has been omitted pursuant to Article 17(2) of Council Regulation (EEC) No 4064/89 concerning non-disclosure of business secrets and other confidential information. The omissions are MERGER PROCEDURE shown thus […]. Where possible the information ARTICLE 6(1)(b) DECISION omitted has been replaced by ranges of figures or a general description. To the notifying party Dear Sir/Madam, Subject: Case No COMP/M.2192 – SmithKline Beecham/Block Drug Notification of 17.11.2000 pursuant to Article 4 of Council Regulation No 4064/89 1. On 17 November, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EEC) No 4064/89 (“the Merger Regulation”), by which the UK company, SmithKline Beecham plc (“SB”) notified its intention to acquire sole control over the US company, Block Drug Company Inc. (“Block Drug”), through purchase of shares. 2. Following examination of the notification, the Commission has concluded that the notified operation falls within the scope of the said Council Regulation and does not raise serious doubts as to its compatibility with the common market and the EEA agreement.
[Show full text]
Annual Report 2015
Annual Report 2015 2015 saw substantial progress to accelerate new product sales growth and strengthen our Pharmaceuticals, Vaccines and Consumer Healthcare businesses Overview of 2015 Strategic report “ In 2015, we made substantial progress to accelerate new product sales growth, integrate new businesses in Vaccines and Consumer Healthcare and restructure our global Pharmaceuticals business. This progress means the Group is well positioned to return to core earnings growth in 2016.” Sir Andrew Witty, Chief Executive Officer Governance & remunerationPerformance Financial statements summary Investor information £23.9bn £10.3bn £5.7bn £3.9bn Group turnover Total operating profit Core operating profit Cash dividends paid (up 6% CER/up 1% CER (up >100% CER) a (down 9% CER/down 3% in 2015 pro-forma) a CER pro-forma)a £2.0bn 174.3p 75.7p 10 0 % New product sales b Total earnings per share Core earnings per share Markets now operating (up >100%) (up >100%, primarily (down 15% CER, primarily new commercial model reflecting impact of reflecting short-term dilution transaction gains) of the Novartis transaction)a ~40 20 ~13 % 1st Potential new medicines Potential to file up to Estimated internal In Access to Medicine and vaccines profiled at R&D 20 assets with regulators rate of return in R&D Index event, 80% of which have by 2020 in 2015 potential to be first-in-classc Footnotes a We use a number of adjusted measures to report the performance of our business, as described on page 54. These include core results, CER growth rates and pro-forma CER growth rates. A reconciliation of total results to core results is set out on page 62.
[Show full text]
Internship Report
Internship Report on “DISTRIBUTION OPERATION AND DEVELOPMENT OF GLAXOSMITHKLINE BANGLADESH LIMITED: A REPORT ON DISTRIBUTION PROCESS OF A RENOWNED CONSUMER HEALTHCARE COMPANY IN BANGLAFDESH OF DHANMONDI TERRITORY” Submitted To Mr. Riyashad Ahmed Assistant Professor BRAC Business School BRAC University Submitted By Azhar Amin Chowdhury ID: 14304134 BRAC Business School BRAC University Course: BUS400 Summer 2018 29th July, 2018 Letter of Submission 29th July, 2018 Mr. Riyashad Ahmed Assistant Professor, BRAC Business School BRAC University Subject: Submission of Internship Report Dear Sir, This is my great honor to submit the internship report that I have prepared for last 3 months long in GlaxoSmithKline Limited Bangladesh, under sales department. The title of the report is “Distribution Operation and Development of GlaxoSmithKline Bangladesh Ltd: A Report on Distribution Process of a Renowned Consumer Healthcare Company in Bangladesh of Dhanmondi territory”. This report has been prepared to fulfill the requirement of my internship program at my assigned organization, GlaxoSmithKline Bangladesh Limited. The report is the final outcome of successful completion of my internship program at GSK. In my report I have described the work process followed by my assigned department and tried to identify some drawback of the process and gave some recommendation by using my learnings from undergrad life. I would like to articulate my gratitude for your excellent guidance in preparing the report. It would be a great achievement for me if you find this
[Show full text]
Annual Report 2017
Annual Report Image HIV virus 2 017 GSK Annual Report 2017 GSK is a science-led global healthcare company In the Strategic report Our new CEO discusses Measuring performance 2017 performance and our and managing risk new long-term priorities See pages 05–07 See pages 18–21 How we create Innovation and Performance long-term value in each of our three businesses See pages 08–09 See pages 22–41 Industry trends How our three businesses together contribute to our Trust priority See pages 10–11 See pages 42–51 Our new long-term priorities: Financial review Innovation, Performance and Trust See pages 12–17 See pages 52–78 Cover image Cautionary statement 30 years after developing the first HIV See the inside back cover of this document medicine, our research into treatment and for the cautionary statement regarding prevention of HIV continues. We remain forward-looking statements. at the forefront of helping people living with HIV, driving innovation and working with communities all over the world. 01 GSK Annual Report 2017 Strategic report Governance and remuneration Financial statements Investor information Our financial performance in 2017a £30.2bn AER +8% £6.7bn AER +51% Group turnover CER +3% New product salesb CER +44% £4.1bn AER +57% £8.6bn AER +12% Total operating profit CER +39% Adjusted operating profit CER +5% 31.4p AER +67% 111.8p AER +11% Total earnings per share CER +36% Adjusted earnings per share CER +4% £6.9bn £3.4bn £3.9bn 80p Net cash flow from Free cash flow Dividends declared 2017 dividend operating activities for 2017 per
[Show full text]